Skip to main content

Table 2 Percent differences within metabolic syndrome and insulin resistance subgroups in LDL-C, total cholesterol, HDL-C and triglycerides

From: Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

 

Abdominal Obesitya

TG

HDL-C

SBP (DBP)

FG

HOMA-IR

 

No

Yes

<150 mg/dL

≥150 mg/dL

≥40 mg/dL

<40 mg/dL

<130 (85) mmHg

≥130 (85) mmHg

<100 mg/dL

≥100 mg/dL

<2.72

2.72-4.81

>4.81

 

n = 20-36

n = 177-196

n = 62-77

n = 142-155

n = 82-99

n = 119-135

n = 11-21

n = 194-205

n = 52-75

n = 144-165

n = 57-81

n = 68-78

(n = 69-79

LDL-C, mg/dL (95 % CI)

             

 E/S20 - A10b

−8.6 (−17.3, 0.1)

−13.9 (−17.6, −0.3)*

−15.8 (−21.7, −10.0)*

−11.8 (−15.9, −7.7)*

−14.3 (−19.3, −9.2)*

−12.2 (−16.7, −7.8)*

−17.8 (−31.8, −3.8)*

−12.9 (−16.3, −9.4)*

−9.5 (−15.4, −3.6)*

−14.9 (−19.0, −10.9)*

−11.1 (−16.7, −5.4)*

−15.9 (−21.8, −10.0)*

−12.3 (−18.2, −6.5)*

 E/S20 - A20b

−9.1 (−17.8, −0.4)*

−10.4 (−14.1, −6.8)*

−12.0 (−17.7, −6.3)*

−9.3 (−13.4, −5.2)*

−9.1 (−14.1, −4.1)*

−11.1 (−15.6, −6.6)*

−9.8 (−21.8, 2.2)

−10.3 (−13.8,-6.8)*

−6.8 (−12.7, −0.9)*

−11.9 (−16.0, −7.9)*

−12.3 (−17.9, −6.7)*

−10.3 (−16.2, −4.4)*

−7.7 (−13.5, −1.8)*

 E/S40 - A40b

2.0 (−8.4, 12.4)

−9.3 (−12.8, −5.8)*

−9.8 (−16.0, −3.6)*

−7.2 (−11.2,-3.2)*

−5.90 (−11.3, −0.5)*

−9.2 (−13.4, −4.9)*

−2.4 (−13.5, 8.8)

−8.5 (−12.0, −5.0)*

−7.6 (−14.0,-1.1)*

−8.0 (−11.9,-4.1)*

−8.1 (−14.2, −2.0)*

−8.9 (−14.5, −3.2)*

−7.1 (−12.9, −1.4)*

TC, mg/dL (95 % CI)

             

 E/S20 - A10b

−4.8 (−11.2, 1.5)

−7.7 (−10.3, −5.1)*

−10.2 (−14.4, −5.9)*

−5.8 (−8.8, −2.9)*

−7.6 (−11.2, −3.9)*

−7.0 (−10.2, −3.8)*

−10.6 (−20.8, −0.5)*

−7.0 (−9.5, −4.5)*

−4.3 (−8.5, 0.0)

−8.7 (−11.6, −5.7)*

−6.1 (−10.2, −2.0)*

−8.4 (−12.6, −4.1)*

−7.1 (−11.4, −2.9)*

 E/S20 - A20b

−4.8 (−11.0, 1.5)

−5.5 (−8.1, −2.8)*

−7.1 (−11.2, −3.0)*

−4.4 (−7.4, −1.4)*

−4.6 (−8.2,-1.0)*

−6.0 (−9.2, −2.7)*

−4.6 (−13.3, 4.2)

−5.5 (−8.0, −2.9)*

−2.8 (−7.1, 1.5)

−6.6 (−9.6, −3.7)*

−7.4 (−11.4, −3.3)*

−4.8 (−9.1, −0.5)*

−3.7 (−8.0, 0.6)

 E/S40 - A40b

−3.0 (−10.6, 4.6)

−4.8 (−7.3, −2.2)*

−4.3 (−8.8, 0.2)

−4.5 (−7.4, −1.6)*

−3.1 (−7.0, 0.9)

−5.3 (−8.4, −2.2)*

−1.0 (−9.0, 7.0)

−4.8 (−7.3, −2.2)*

−4.9 (−9.6, −0.2)*

−4.1 (−7.0, −1.3)*

−5.8 (−10.2,-1.3)*

−4.8 (−8.9, −0.6)*

−2.6 (−6.8, 1.5)

HDL-C, mg/dL (95 % CI)

             

 E/S20 - A10b

2.4 (−4.5, 9.3)

3.3 (0.4, 6.2)*

3.9 (−0.7, 8.5)

3.2 (0.0, 6.5)

1.3 (−2.6, 5.3)

5.0 (1.4, 8.5)*

9.8 (−1.3, 20.8)

3.0 (0.3, 5.7)*

3.2 (−1.4, 7.8)

3.4 (0.2, 6.6)*

4.2 (−0.2, 8.7)

4.1 (−0.5, 8.8)

1.4 (−3.2, 6.0)

 E/S20 -A20b

−0.2 (−7.0, 6.7)

1.6 (−1.3, 4.5)

2.0 (−2.5, 6.5)

0.8 (−2.5, 4.0)

0.0 (−3.9, 3.9)

2.2 (−1.4, 5.7)

8.9 (−0.6, 18.4)

0.4 (−2.3, 3.2)

0.8 (−3.9, 5.4)

1.3 (−1.9, 4.5)

3.0 (−1.4, 7.4)

−0.3 (−5.0, 4.4)

0.2 (−4.4, 4.9)

 E/S40 - A40b

−2.8 (−11.0, 5.5)

4.7 (1.9, 7.5)*

5.0 (0.1, 9.9)*

3.6 (0.5, 6.7)*

4.3 (0.1, 8.6)*

3.7 (0.4, 7.1)*

9.1 (0.3, 17.9)*

3.5 (0.7, 6.2)*

4.8 (−0.3, 9.9)

3.2 (0.1, 6.3)*

5.6 (0.8, 10.5)*

4.9 (0.4, 9.4)*

1.1 (−3.5, 5.6)

TG, mg/dL (95 % CI)

             

 E/S20 - A10b

−7.4 (−20.3, 6.4)

0.1 (−4.7, 4.6)

−0.9 (−9.0, 6.2)

−1.5 (−6.8, 3.5)

1.8 (−5.2, 8.3)

−3.1 (−9.1, 2.4)

−2.7 (−20.8, 11.1)

−0.8 (−5.4, 3.6)

−0.3 (−7.9, 7.7)

−1.3 (−6.8, 3.9)

−3.9 (−11.7, 3.9)

1.4 (−6.1, 8.8)

−0.3 (−8.1, 6.9)

 E/S20 - A20b

−0.8 (−12.9, 11.5)

3.5 (−1.3, 8.2)

7.3 (−0.2, 14.8)

0.3 (−5.0, 5.7)

4.3 (−2.3, 11.1)

1.7 (−4.1, 7.3)

2.1 (−11.1, 16.2)

2.9 (−1.7, 7.5)

2.4 (−4.7, 10.8)

2.7 (−2.5, 8.3)

−0.1 (−8.0, 8.2)

4.2 (−3.5, 12.2)

3.6 (−4.0, 10.5)

 E/S40 - A40b

−0.3 (−19.6, 15.4)

−0.4 (−4.9, 4.1)

2.2 (−6.6, 10.9)

−1.4 (−6.4, 3.5)

−1.6 (−8.8, 5.1)

0.4 (−5.3, 5.8)

−2.7 (−18.5, 11.5)

−0.1 (−4.7, 4.5)

−6.1 (−13.9, 2.6)

1.9 (−3.4, 6.9)

−4.0 (−12.7, 4.9)

−1.2 (−8.2, 5.7)

4.8 (−3.3, 12.3)

  1. A10/20/40 = atorvastatin 10/20/40 mg; E = ezetimibe 10 mg; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; HOMA-IR = Homeostasis Model Assessment of Insulin Resistance; LDL-C = low density lipoprotein cholesterol, n = number of patients in subgroup (some numbers vary slightly between parameters), S20/40 = simvastatin 20/40 mg; SBP (DBP) = systolic blood pressure (diastolic blood pressure); SD = standard deviation; TG = triglycerides
  2. *Confidence intervals of difference parameters do not contain 0 aabdominal obesity = waist circumference ≥40 inches for males or ≥35 inches for females bbetween-treatment differences (E+S minus A) based on ANOVA model with terms for subgroup (baseline abdominal obesity, TG, HDL-C, blood pressure, fasting glucose, and HOMA-IR, based on subgroup being analyzed), baseline stratum, treatment group, and the interaction of treatment group and subgroup Values in parentheses = 95% confidence intervals